Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

John Carroll

Editor & Founder

Amber Tong

Senior Editor

Bristol Myers Squibb made a megablockbuster bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

John Carroll

Editor & Founder

Amber Tong

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Bris­tol My­ers wins a megablock­buster bet with TYK2 FDA ap­proval — and there's a big bonus for the la­bel

Editor & Founder

Senior Editor

Sign up to read this article for free.

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label